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Background: Angiogenesis is integral for embryogenesis, and targeting angiogenesis improves the 
outcome of many pathological conditions in patients. TBX20 is a crucial transcription factor for 
embryonic development, and its deficiency is associated with congenital heart disease. 
However, the role of TBX20 in angiogenesis has not been described. 
Methods: Loss- and gain-of-function approaches were used to explore the role of TBX20 in 
angiogenesis both in vitro and in vivo. Angiogenesis gene array was used to identify key 
downstream targets of TBX20. 
Results: Unbiased gene array survey showed that TBX20 knockdown profoundly reduced 
angiogenesis-associated PROK2 gene expression. Indeed, loss of TBX20 hindered endothelial cell 
migration and in vitro angiogenesis. In a murine angiogenesis model using subcutaneously 
implanted matrigel plugs, we observed that TBX20 deficiency markedly reduced PROK2 
expression and restricted intra-plug angiogenesis. Furthermore, recombinant PROK2 administration 
enhanced angiogenesis and blood flow recovery in murine hindlimb ischemia. In zebrafish, 
transient knockdown of tbx20 by morpholino antisense oligos (MO) or genetic disruption of tbx20 
by CRISPR/Cas9 impaired angiogenesis. Furthermore, loss of prok2 or its cognate receptor prokr1a 
also limited angiogenesis. In contrast, overexpression of prok2 or prokr1a rescued the impaired 
angiogenesis in tbx20 deficient animals. 
Conclusions: Our study identifies TBX20 as a novel transcription factor regulating angiogenesis 
through the PROK2-PROKR1 pathway in both development and disease, and reveals a novel mode 
of angiogenic regulation whereby the TBX20-PROK2-PROKR1 signaling cascade may act as a 
“biological capacitor” to relay and sustain the pro-angiogenic effect of VEGF. This pathway may be 
a therapeutic target in the treatment of diseases with dysregulated angiogenesis. 
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We report a novel TBX20-choreographed signaling pathway that functions as a 
proangiogenic capacitor to regulate developmental and pathological angiogenesis.  
In this signaling pathway, with VEGF stimulation, the transcription factor TBX20 
upregulates PROK2, which is secreted from endothelial cells (ECs), engages its receptor 
PROKR1, and thereby promotes angiogenesis in an autocrine manner. 
This signaling pathway (TBX20-PROK2-PROKR1) is highly conserved as it functions in 
zebrafish vascular development, and the angiogenic response to ischemia in a mouse 
model of peripheral arterial disease (PAD). 
Our study indicates the selective role of TBX20 in endothelial migration but not 
proliferation. 
What are the clinical implications? 
Stimulating this pathway may facilitate therapeutic angiogenesis in patients with 
ischemic syndromes such as PAD. 
Treatment with recombinant PROK2, the critical effector of TBX20, improves blood 
perfusion and functional recovery in the mouse PAD model. 
Mutations in TBX20, PROK2, or PROKR1 gene precipitate cardiovascular or neuronal 
diseases in humans. 
Our data highlight the therapeutic potential of PROK2 in augmenting functional 
































T-box 20 (TBX20) encodes a key transcription factor (TF) that is expressed in the heart, eyes, 
ventral neural tube, and limbs during embryonic development 1. It belongs to the 
phylogenetically conserved family of T-box genes that share a common T-box DNA-binding 
domain. In zebrafish, tbx20 is expressed in the developing heart and dorsal aorta2, 3, and regulates 
cardiac development4. Tbx20 knockout in mice causes a variety of cardiac defects and results in 
embryonic lethality around E10.55-7. In humans, mutations in TBX20 are associated with a 
complex spectrum of developmental abnormalities, including defects in septation, chamber growth, 
valvulogenesis and cardiomyopathy8. 
TBX20 regulates endocardial cushion cell proliferation, extracellular matrix gene 
expression and septation9, 10 , in part via modulation of Lef1 and the Wnt/β-catenin pathway11. In 
addition, TBX20 promotes heart chamber formation in part through repression of TBX25-7. 
Whereas a partial deficiency of TBX20 may cause congenital heart defects, a greater deficiency of 
TBX20 hinders motoneuron development12. 
Tbx20 is also expressed in the adult heart, where overexpression of Tbx20 in adult 
cardiomyocytes promotes proliferation13, 14 and improves myocardial infarction outcomes in 
mouse model 18. In endothelial cells (ECs), TBX20 upregulates PPAR-γ and suppresses the 
generation of reactive oxygen species and the expression of adhesion molecules generated in 
response to oxidized low-density lipoproteins15. However, it is unknown whether TBX20 is 
involved in blood vessel formation and controls angiogenic processes. 
The chimeric heterokaryon model was first used to identify novel genes in nuclear 
reprogramming to pluripotency16. We have adopted the model to identify novel genes in 
endothelial development17. In this model, murine embryonic stem cells (ESCs) are fused with 
adult human ECs, and RNA-seq is performed at intervals to assess changes in global gene 
expression of the resulting hybrid cells. We found that factors maintaining endothelial phenotype 
act on the ESCs to induce the expression of genes associated with endothelial lineage17. Using this 
model, we discovered novel genes implicated in endothelial development. TBX20 was upregulated 
early after cell fusion in this chimeric heterokaryon model, which prompted us to explore the role of 
TBX20 in endothelial development. Our subsequent work illuminates a new TBX20-choreographed 
molecular pathway for developmental and pathological angiogenesis.  
 
Methods  
The data, analytic methods, and study materials will be made available to other researchers for 
purposes of reproducing the results or replicating the procedure upon request. 
 
Animal husbandry 
All animals were maintained in a specific pathogen-free facility at Houston Methodist Research 
Institute in Houston. Animal use and care were approved by the Houston Methodist Animal Care 
Committee in accordance with institutional animal care and use guidelines. NOD-SCID mice 
were generated in our laboratory. Zebrafish AB wild type, mutant and Tg(fli1:EGFP)y1 fish lines 
were maintained and bred as described previously 18, 19. 
 
Matrigel plug assay 
To assess the role of Tbx20 in angiogenesis in vivo, matrigel was mixed with 50 ng/ml VEGF, 
30 U/ml heparin to stabilize VEGF20, and with 2 μM scramble siRNA or siRNA targeting 
Tbx20 in a final volume of 400 μL and injected subcutaneously into the lower abdominal region 
of SCID mice. After five days, the matrigel plugs were removed for FACS analysis, RNA 
extraction or histology analysis. The investigator who analyzed the matrigel plugs was blinded 
to the initial treatment. 
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Murine hindlimb ischemia 
Hindlimb ischemia was induced in 9-month old male wild type mice as previously reported with 
slight modification20-22. Briefly, unilateral hindlimb ischemia was induced by ligating the 
femoral artery and its major branches. Afterwards, the mice were housed individually and blood 
flow in the affected and control limbs was imaged up to 21 days. In some experiments, 
recombinant PROK2 proteins (0.1 μg/g body weight) or PBS was injected i.m. immediately and 
7 days after surgery. Blood perfusion was monitored before and immediately after surgery, and 
4, 7, 11 and 14 days post-operatively. The clinical ischemia score index was used to assess tissue 
loss, as modified from the previously reported method23. The criteria used were: 0 - No changes; 
1 - Discoloration/Necrosis of the nails; 2 - Discoloration/Necrosis of the toes; 3 - Foot Necrosis; 
4 - Leg Necrosis (up to the gastrocnemius muscle); 5 - Autoamputation (loss of limb). There 
were two independent observers, blinded to the group assignment. At day 14 in the 
postoperative period, the hindlimb muscles from the operated and contralateral limbs collected 
for histology. Eight male mice were used for each experimental group. Total capillary density of 
the ischemic hindlimb cross sections was determined by staining the slides with rabbit antimouse 
CD31 (BD Biosciences), followed by horseradish peroxidase–conjugated secondary 
antibody. 
 
Laser Doppler based tissue perfusion measurement 
Blood flow to the ischemic or non-operated (nonischemic) hindlimb was assessed using a 
PeriScan PIM3 laser Doppler system (Perimed AB, Sweden) as described previously 16,36. 
Animals were prewarmed to a core temperature of 37.5 °C and heart rate was constantly 
monitored for signs of stress from overheating. Hindlimb blood flow was measured pre- and 
postoperatively on selected days (0, 4, 7, 11 and 14). Blood perfusion rate was measured via 
laser Doppler scans. The level of perfusion in the ischemic and unoperated hindlimbs was 
quantified using the mean pixel value within the region of interest, and the relative changes in 
hindlimb blood flow were expressed as the ratio of the left (ischemic) over right (unoperated) 
Laser Doppler-detected blood perfusion. 
 
Generation of zebrafish mutants using CRISPR/Cas9 
The CRISPR/Cas9-mediated gene knockout technology in wild type AB line zebrafish was 
performed as previously described24. In brief, the target sequences for tbx20, prok2 and prokr1a 
were 5’- TGTGCTAATGGACATAGTTC-3’, 5’-GGATGCACATTCGGAGACTG-3’ and 5’- 
GGCAATATCAGACTTTCTGG-3’, respectively. Complementary target oligonucleotides were 
annealed and inserted into pT7-gRNA vector. Guide-RNA (gRNA) was synthesized using 
HiScribe T7 Quick High Yield RNA Synthesis kit. The pCS2-nCas9n was linearized using NotI 
and capped Cas9 mRNA was synthesized using mMESSAGE mMACHINE SP6 kit. The gRNA 
(50-100 ng/ l) and Cas9 mRNA (150-200 ng/ l) was mixed and injected into one-cell stage WT 
AB embryos. 
For detecting the zebrafish mutants, genomic DNA was extracted from individual 
zebrafish larva and a short genomic region (300-500 bp) flanking the target site was PCR 
amplified. Purified PCR products (200 ng) were denatured and reannealed, and then digested 
with T7 Endonuclease I (NEB). PCR products of positive mutants were subcloned into pMD20- 
TA vector (Clontech). After transformation into competent cells and overnight culture at 37°C, 
single colony was selected for sequencing. 
 
RNA extraction and Quantitative Real-Time PCR (qRT-PCR) 
qRT-PCR in zebrafish and mice was performed as previously described18, 25-27. Primers used in 
zebrafish study were list in Table S1. Please see supplementary materials for details. 
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Whole-mount alkaline phosphatase staining 
Zebrafish embryos were fixed in 4% paraformaldehyde (PFA) at 3 days post-fertilization and 
stained for endogenous alkaline phosphatase activity similar to previously described 28, 29. 
Briefly, the embryos were fixed in 4% PFA overnight at room temperature, and were serially 
dehydrated and permeabilized in 25%, 50%, 75% methanol in PBST (phosphate buffered saline 
with 0.1% Tween-20, pH 5.5) (v/v), and 100% methanol, following by rehydrated in 75%, 50% 
and 25% methanol and finally in PBST. After equilibrated with alkaline phosphatase buffer, the 
embryos were stained using the NBT/BCIP solution at room temperature for 20 minutes. The 
reaction was stopped with stop buffer (PBST with 0.25 mM EDTA, pH 2.2). Embryos were 
mounted in glycerol for image capture. 
 
Confocal imaging and data analysis 
Anaesthetized embryos at indicated stage were mounted in 1.0% low-melt agarose (Sigma 
Aldrich) for imaging18. Images were acquired by using an Olympus FluoView FV1000 laser 
scanning confocal microscope. Z-stacks were acquired with a 3 M z-step, and images were 3D 




Results were expressed as mean±SEM, and statistical analysis was performed using Student’s ttest, 
one-way or two-way analysis of variance (ANOVA) followed by Sidak’s multiple 
comparisons test using Prism software. *p<0.05 was considered statistically significant. **, p ≤ 
0.01, ***, p ≤ 0.001, ****, p ≤ 0.0001. 
 
Results 
Tbx20 is robustly upregulated in a heterokaryon model 
To examine the Tbx20 gene expression in endothelial differentiation, two model systems were 
used, one is the mESC differentiation to ECs and the other one is heterokaryon induced 
differentiation of pluripotent stem cells into endothelial lineage. During the mESC differentiation 
into endothelial lineage17, Tbx20 gene expression was upregulated by 16-fold at day 8 of 
differentiation compared with mESCs (Fig. S1a). In a heterokaryon model17, fusing mESC with 
HUVECs induced differentiation of pluripotent stem cells toward endothelial lineage. We found 
that Tbx20 gene expression was upregulated and peaked at 4-fold at 6 hours after heterokaryon 
formation compared with co-culture control (CT, Fig. S1b). 
 
Tbx20 is essential for developmental angiogenesis in zebrafish 
Based on our findings from the heterokaryon model, we hypothesized that TBX20 
transcriptionally regulates vascular development. Accordingly, we first knocked down tbx20 in 
zebrafish embryos by injecting tbx20 MO at the one-cell stage embryo of Tg(fli1:EGFP)y1 
zebrafish. These animals express enhanced green fluorescent protein (EGFP) in the 
endothelium30, permitting visualization of vascular development in both trunk and yolk sac 
regions. At 30 hours post-fertilization (hpf), the tbx20 knockdown (KD) embryos, compared to 
controls, showed no apparent change in vasculogenesis as evidenced by normal dorsal aorta and 
cardinal vein formation (Fig. 1a). At this time point, intersegmental vessels (ISVs), which sprout 
from dorsal aorta via angiogenesis including endothelial proliferation and migration31, reached 
the dorsal roof of the neural tube in control embryos (Fig. 1a, 1c and Fig. S1c). In contrast, ISVs 
sprouted only halfway through their dorsal trajectory and stalled at the boundary between the 
notochord and neural tube in tbx20 morphants (Fig. 1a, 1c and Fig. S1c). In addition, tbx20 
deficiency suppressed the development of subintestinal vessels (SIVs), which form bilaterally 
over the dorsal-lateral aspect of the zebrafish yolk at 3 day post-fertilization (dpf)32, in the shape 
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of a basket that extends from the ventral edge of the somite29 (Fig. 1b, 1c and Fig. S1d). 
Coinjection of the zebrafish tbx20 mRNA, which lacked the MO targeting site, significantly 
rescued the ISV and SIV defects in tbx20 morphants (Fig. 1a-c, Fig. S1c & d). All the above data 
suggest that tbx20 is required for developmental angiogenesis. 
Since MO-mediated transient gene KD could have off-target effects33, we also generated 
tbx20 knockout (KO) mutants to further validate the MO-induced vascular defects. We generated 
the tbx20 KO zebrafish mutants using CRISPR/Cas9 to target the third exon of tbx20 (Fig. 1d). 
Zebrafish full-length tbx20 encodes a protein of 446 amino acid (AA). The tbx20 mutants had a 
4-bp deletion starting at the 453 nucleic acid position (Fig. 1e), resulting in frameshift and a 
premature stop codon encoding a truncated protein of only 193 AA (Fig. 1f). This mutation 
disrupted the original T-box domain (98-290 AA) and the DNA binding domain34, designed to 
abolish its transcriptional activity. 
Blood vessels in tbx20 mutants showed incomplete vessel length, attenuated sprouting of 
SIVs and reduced vascular area compared with controls (Fig. 1g & h) as examined using 
wholemount staining for endogenous alkaline phosphatase activity29. These phenotypes are 
congruent with tbx20 morphants, suggesting that the angiogenic phenotype of tbx20 morphant was 
not due to MO off-target effects, and that tbx20 regulates in vivo vascular development in zebrafish. 
Previous studies found that constitutive KO mutations, but not transient KD, may activate 
compensatory mechanisms35 and thus cause discrepancies in the observed phenotype between 
KD and KO animals. However, we observed impaired developmental angiogenesis in both tbx20 
KD and KO, suggesting that tbx20 plays a critical role in developmental angiogenesis, 
uncompensated by other mechanisms. 
ISV angiogenic sprouts originate at about 20 hpf from the dorsal aorta, which condenses 
as a distinct cord of ECs at the trunk midline starting at the 15 somite stage (16.5 hpf)31. Since 
tbx20 is reported to regulate heart development, we next examined whether the impaired 
angiogenesis is secondary to a defect of heart development and associated hemodynamic 
perturbations. We used the pan-cardiac marker, cardiac-myosin light chain-2 (cmlc2), to 
examine the formation of arterial precursors as reported36. At 24 hpf, cmlc2 expression in tbx20 
morphants were comparable to that in control animals, suggesting that the specification of 
arterial precursors proceeds normally in tbx20-MO injected animals. At 30 hpf, we did not 
observed abnormal heart development in low dose tbx20 MO injected animals (Fig. S2 and Table 
S2), which agreed with previous report that tbx20 is not essential for the early (up to 24 hpf) 
differentiation or morphogenesis of the heart4. Altogether, these data indicate that the impaired 
angiogenesis in Tbx20-deficient animals is not an indirect effect of disturbed hemodynamics 
caused by dysregulated heart development. 
 
Tbx20 is required for pathological angiogenesis in mice 
To determine if Tbx20 has a role in pathological angiogenesis in adult animals, we prepared 
matrigel that was mixed with Tbx20 siRNA or scrambled control siRNA, and injected the 
matrigel subcutaneously into NOD-SCID mice. The matrigel is in a liquid form at 4 °C, and 
condenses into a solid plug when injected into mice. This model is widely used to assess 
angiogenesis. Our data demonstrated that matrigel plugs containing the scrambled siRNA 
showed robust angiogenic response, and were imbued with vessels containing red blood cells as 
evidenced by bright field imaging and by HE staining (Fig. 2a & b). By contrast, intra-plug 
vessels and blood content was markedly reduced in those plugs containing Tbx20 siRNA (Fig. 2 
a & b). FACS analysis of the cell content in matrigel plugs revealed a decrease in CD144+ ECs 
(Fig. 2c & d) from Tbx20 siRNA-containing matrigel plugs (0.41% vs 4.96% in CT). We 
verified successful KD of Tbx20 gene expression in the matrigel plug using qRT-PCR (Fig. 2e). 
To explore the role of TBX20 in angiogenesis in vitro, we knocked down TBX20 in 
human umbilical vein ECs (HUVECs) and examined the effect on tube formation, migration and 
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proliferation. We generated a stable TBX20 KD line and CT HUVECs using lentiviral vector 
mediated delivery of shRNA against TBX20 or scrambled CT shRNA. Compared with CT cells, 
qRT-PCR analysis showed a 50% decrease in TBX20 gene expression (Fig. 2f), and western blot 
analysis revealed a 60% reduction in protein levels (Fig. 2g) in the TBX20 KD cells. TBX20 KD 
HUVECs maintained the normal cobblestone morphology compared with CT cells (Fig. S3a). 
Since angiogenesis consists of endothelial migration and proliferation, we examined 
these functions in TBX20 KD cells. The TBX20 KD did not significantly reduce cell proliferation 
rate (Fig. S3b) albeit slightly reducing the cell fraction in G2/M phase (Fig. S3c & d). TBX20 KD 
did not alter acLDL uptake (Fig. S3e & f), the synthesis of NO (Fig. S3g), and the expression of 
CD31 and CD144 (Fig. S3h-j), compared with CT cells. However, TBX20 KD markedly 
impaired VEGF-induced tube formation (Fig. 2h), and suppressed cell migration in a scratch 
assay (Fig. 2i & j) Altogether, these data suggest that TBX20 regulates angiogenesis mainly 
through EC migration. 
 
Prokineticin 2 (PROK2) mediates the effect of TBX20 
To identify downstream molecules of TBX20 in angiogenesis, we examined the gene expression 
of 84 angiogenesis-related genes using a Qiagen Angiogenesis RT Profiler PCR Array. Sixteen 
genes were downregulated over 2-fold in the TBX20 KD HUVECs compared with CT (Fig. 3a). 
Among them, PROK2 was downregulated over 12 fold, one of the most pronouncedly responsive 
genes in TBX20 KD cells. 
PROK2 is a secreted protein and is known to have diverse functions in angiogenesis37, 38, 
behavioral circadian rhythm39, olfactory bulb morphogenesis40 and reproductive function41. In 
adult zebrafish, prok2 is involved in both constitutive and injury-induced neurogenesis42. To 
examine whether PROK2 mediated the impaired angiogenic processes in TBX20 KD cells, we 
determined the rescue effect of PROK2 on the defective network formation in TBX20-deficient 
HUVECs. As expected, supplementation with exogenous PROK2 restored normal tube 
formation in TBX20 KD HUVECs (Fig. 3b). 
In addition, we generated TBX20 overexpression (OE) HUVECs and examined the 
PROK2 gene expression. Both qRT-PCR (Fig. 3c) and western blot analysis (Fig. 3d) validated 
the stable overexpression of TBX20. As expected, TBX20 OE further promoted EC migration 
(Fig. 3e), and strongly upregulated PROK2 gene expression (Fig. 3f). Similarly, Prok2 gene 
expression was downregulated from matrigel plugs containing Tbx20 siRNA compared with the 
ones with CT siRNA (Fig. 3g). Furthermore, knockdown of tbx20 also diminished prok2 
expression in zebrafish embryo (Fig. 3h). Since VEGF activates the major proangiogenic 
pathway for angiogenesis, we thus assessed hierarchical relations of VEGF, TBX20 and PROK2 
in HUVECs. VEGFA165 stimulation upregulated TBX20 and PROK2 gene expression (Fig. 3i & 
j), an effect that was abolished by TBX20 KD (Fig. 3k & l), suggesting that TBX20 augments 
VEGF-induced PROK2 gene expression. Although TBX20 knockdown also robustly 
downregulated FGF1 and FGFR3 expression (Fig. 3a), Fgf1 and Fgfr3 overexpression failed to 
rescue the angiogenic defects in Tbx20-deficient animals (Fig. S4a & b). Collectively, these 
results suggest that PROK2 functions downstream of TBX20 in regulating angiogenesis. 
Prok2 regulates developmental angiogenesis 
We postulate that loss of prok2 would phenocopy the angiogenesis defects in tbx20 morphants 
since Prok2 acts downstream of Tbx20. Indeed, prok2 KD abolished ISV formation at 30 hpf 
(Fig. 4a & c) and SIV development at 3 dpf (Fig. 4b & c), similar to that in tbx20 morphants. The 
ISV and SIV defects caused by prok2 knockdown were largely reversed by the administration of 
zebrafish prok2 mRNA that did not include the MO targeting site (Fig. 4a-c, Fig. S5a & b). 
We then generated prok2 KO zebrafish mutants (Fig. 4d-f), which showed abnormal SIV 
formation with reduced vessel area, decreased SIV length and attenuated sprouting (Fig. 4g & h). 
Altogether, the prok2 deficiency phenocopied the tbx20 deficiency. These findings suggest that 
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PROK2 exerts its angiogenic effects largely through PROKR1 
PROK2 signals through two G protein coupled receptors, prokineticin receptor (PROKR) 143 and 
244. PROKR1 is reported to mediate the pro-angiogenic effect of PROK2 in cardiovascular 
system45. In addition, PROKR1 overexpression promotes neovascularization46, while PROKR2 
overexpression induces an inflammatory response47. However, the in vivo genetic evidence for 
PROKR1 in angiogenesis remains unknown. 
There is only prokr1 gene but not prokr2 gene in zebrafish. Zebrafish has two different 
prokr1 genes, prokr1a and prokr1b that are located on chromosome 1 and 13, respectively. 
Zebrafish prokr1a shares the highest homologue to that of mouse and human PROKR1. We thus 
hypothesized that prokr1a encodes the major receptor for Prok2 in zebrafish, and further 
hypothesized that loss-of-function of prokr1a would limit angiogenesis similar to that in prok2 
or tbx20 deficient animals. Indeed, similar to tbx20 and prok2 KD morphants, loss of prokr1a 
resulted in a substantial impairment of ISV formation at 30 hpf and SIV formation at 3 dpf (Fig. 
5a). The ISV and SIV defects caused by prokr1a-MO were alleviated by the administration of 
exogenous prokr1a mRNA which did not contain the MO binding site (Fig. 5a-c, Fig. S6a & b). 
We next generated the prokr1a knockout zebrafish mutant (Fig. 5d-f). Notably, the prokr1a 
mutants manifested less SIV sprouting than control animals at 3 dpf (Fig. 5g & h). These results 
suggest that the Prokr1a, a receptor for Prok2, orchestrates angiogenesis in zebrafish. 
In HUVECs, both putative PROK2 receptors PROKR1 and PROKR2 can be detected on 
the cell surface (Fig. 6a). Both PROKR1 and PROKR2 knockdown by siRNA reduced their 
relative mRNA expression over 70% (Fig. 6b). Interestingly, only PROKR1 knockdown 
significantly impaired PROK2-mediated angiogenesis (Fig. 6c) and cell migration (Fig. 6d), 
suggesting that PROK2 controls angiogenesis and EC migration through PROKR1. In addition, 
PROKR1 KD abolished the PROK2-engaged activation and phosphorylation of ERK1/2 and Akt 
pathway in HUVECs (Fig. 6e-g). All data indicate that PROKR1 mediates the effect of PROK2 
on angiogenesis and endothelial migration. 
prok2 or prokr1a gene overexpression rescues angiogenesis in tbx20 KD animals 
Previous studies demonstrate that PROKR1 signaling induces neovascularization46, whereas 
PROKR2 signaling governs inflammatory response and impairs endothelial integrity47. To 
further verify that Prokr1 is the major GPCR for Prok2 in angiogenesis, we overexpressed 
prokr1a mRNA in prok2 morphants, and found that forced Prokr1a expression corrected 
impaired angiogenesis (Fig. 7a & b). 
Interestingly, loss of prok2, similar to tbx20 deficiency, downregulated prokr1a but not 
prokr1b gene expression (Fig. 7c-e), suggesting that Prok2 positively regulates Prokr1a 
expression during development. We further tested whether prok2-prokr1a signaling mediated the 
effect of Tbx20 on angiogenesis. As expected, injection of prok2 or prokr1a mRNA reversed to 
a large extent restricted angiogenesis caused by Tbx20 or Prok2 deficiency (Fig. 7a & b). 
Collectively, these results suggest that Prok2-activated Prokr1a signaling controls angiogenesis 
downstream of Vegf-induced Tbx20 upregulation. 
 
PROK2 enhances functional recovery from hindlimb ischemia 
To examine whether Tbx20-Prok2 pathway is involved in angiogenesis during hindlimb 
ischemia, we examined the gene expression of Tbx20, Prok2 and Prokr1 during the recovery 
following hindlimb ischemia. Intriguingly, both Tbx20 and Prok2 gene expression were 
increased (Fig. 8a & b), but the Prokr1 gene expression remained stable (Fig. 8c). Notably, 
Tbx20 gene expression was upregulated as early as 4 days after ischemia. 
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Since Prok2 gene expression was elevated at later time points, we hypothesize that early 
application of PROK2 will promote angiogenesis and functional recovery from hindlimb 
ischemia. We injected i.m. recombinant PROK2 protein or vehicle. Notably, we observed 
increased blood perfusion recovery in the ischemic limb with PROK2 treatment (Fig. 8d & f). In 
addition, the PROK2-treated mice were improved clinically, as documented by an observer 
blinded to treatment group using an established clinical scoring system (Fig. 8e). PROK2 
administration also increased gastrocnemius capillary density as shown by greater CD31 staining 
(Fig. 8g). The results suggest that PROK2 treatment enhances functional blood vessel formation 
following hindlimb ischemia injury. 
 
Discussion 
Previous studies showed that the transcriptional factor TBX20 regulates a variety of 
developmental processes, in particular heart development4-8. In this paper, we demonstrate for 
the first time that TBX20 mediates angiogenic processes in vitro; orchestrates vascular 
development in zebrafish; and modulates the angiogenic response to ischemia in mice. We 
identified PROK2 as a downstream target for TBX20, and further validated that PROK2- 
PROKR1 signaling axis mediated the effect of TBX20 on angiogenesis. Thus, our study defined 
a novel TBX20-regulated signaling pathway for angiogenesis (Fig. S7). 
 
Identification of TBX20 as a novel transcription factor for angiogenesis: selective role in 
cell migration 
We identified TBX20 as a candidate for endothelial lineage using a heterokaryon model to 
screen for genes regulating EC development. In this model, an array of EC function-associated 
genes are sequentially activated in the ESC nuclei of chimeric heterokaryons generated by fusing 
human ECs with mouse ESCs. The genes upregulated in this model system are often 
determinants of EC fate or EC identity maintenance. Angiogenesis is an EC function that 
generates microvasculature sprouting from preexisting vasculature. We find that TBX20 plays a 
role in angiogenesis but not in vasculogenesis, the formation of major conduits during 
development. Since vasculogenesis requires de novo generation of angioblasts, it is unlikely that 
TBX20 plays a role in EC lineage establishment. Angiogenesis requires EC migration and 
proliferation, and interestingly, Tbx20 selectively controls EC migration but not proliferation. 
During development, the VEGFR2 signaling pathway is a major regulator of angiogenesis that 
induces both EC migration and proliferation. VEGF triggers many downstream signaling 
cascades (including PI3K-Akt48, PLC- -ERK1/249, SRC-Small GTPase50, p3851 ) that are 
involved in EC migration and/or proliferation52. We will investigate the particular effector(s) of 
VEGFR2 signaling pathway52 responsible for TBX20-regulated angiogenesis in future studies. In 
our preliminary studies, we found that in the in vitro scratch assay, which initiates cell migration, 
TBX20 expression was increased (data not shown), it will be interesting to determine if TBX20 
expression is enriched in tip cells, the cell type that spearheads cell migration during 
angiogenesis. 
 
TBX20-PROK2-PROKR1 signaling in the relay of VEGF activity: a proangiogenic 
capacitor 
Our initial studies suggest that Tbx20 regulates angiogenesis. Taking advantage of Tbx20 as a 
transcription factor, we performed unbiased qRT-PCR array for angiogenic genes to identify the 
Tbx20 downstream target(s). We found that Prok2 was dramatically downregulated in response 
to TBX20 knockdown. Our subsequent in study in animals and in vitro validated that TBX20 
loss- and gain-of-function decreased and increased PROK2 expression, respectively. FGF1 and 
FGFR3 are markedly reduced in TBX20-deficient ECs, but forced expression of these genes 
could not correct disrupted angiogenesis in Tbx20 knockdown animals. Thus, our data suggest 
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that Prok2 is a direct downstream target of TBX20, and that its activity is not dependent upon 
FGF. Importantly, administration of PROK2 enhanced angiogenesis and functional recovery 
from hindlimb ischemia, suggesting that PROK2 can be a potential therapeutic target. PROK2 
signaling controls endothelial migration and angiogenesis preferentially through PROKR1, but 
not PROKR2. PROKR1 KD impairs proper activation and phosphorylation of ERK1/2 and Akt. 
However, a survey of available TBX20 ChIP data failed to reveal TBX20 binding on PROK2 
proximal promoter. Several reasons may account for this: 1. The quality of the ChIP data may 
not be optimal enough to allow for a high-resolution analysis of TBX20 binding to the Prok2 
promoter region. 2. There may be some enhancer region(s) that is far away from the actual gene 
body regulating its expression. 3. Tbx20 may regulate Prok2 expression epigenetically or 
through a non-coding RNA. The detailed mechanism of action by which TBX20 regulates 
PROK2-PROKR1 signaling in angiogenesis warrants further investigation. 
PROK2, known as a member of endocrine gland-derived VEGF family, is expressed in 
the endocrine tissues. In the testis where the turnover of ECs is high, PROK2 and its receptor 
PROKR1 are highly expressed, which may help maintain vascular integrity and density in the 
adult53. During early pregnancy, PROKR1 is expressed in the fetal ECs to support gestation. Our 
study identified the role of this pathway in developmental and pathological angiogenesis. 
Although several GPCR ligands such as S1P or Apelin regulate angiogenesis54-56, they usually 
employ a paracrine mechanism, i.e. other cells that secrete the ligands acting on ECs. We 
elucidated a novel autocrine GPCR signaling cascade in which EC-derived GPCR ligand PROK2 
controls endothelial migration and angiogenesis. Angiogenesis is required for embryogenesis and 
tissue remodeling/repair following ischemia. Because partial VEGF loss- or gain-of-function 
causes embryonic lethality57-59, it is essential to evolve multiple layers of control mechanisms to 
ensure proper VEGF signaling, e.g. an alternative pathway to sustain the proangiogenic effect. 
We speculate that this TBX20-PROK2-PROKR1 pathway may thereby function as a “biological 
capacitor” to relay and prolong the angiogenesis-promoting effect of VEGF. To conclude, our 
studies highlight a previously unappreciated mechanism for angiogenesis in which VEGFstimulated 
TBX20 activates PROK2-PROKR1 signaling. This pathway might be therapeutically 
targeted to treat diseases associated with dysregulated angiogenesis. 
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